OakChart

Edgewise Therapeutics Inc

EWTXHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 1:37 PM ET

47.76+1.23 (2.64%)
2026-11-11 19:37 CET
Market cap
5,094.24 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
1,009.60 USD m
Free cash flow, TTM
-202.28 USD m
EPS diluted, TTM
8.18
P/E
5.84
Compare

Price

EWTX against its 20, 50 and 200-day averages
2050200beatmiss
30.0040.0050.003.2M6.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26EWTXclose 47.7620-day 40.4650-day 41.18200-day 36.8447.76

2.1% under the 52-week high of 48.78 on 9 Nov 2026. 52-week low 18.10 on 11 Nov 2025. Last 15 sessions, 32.9% high to low

Profile

EWTX
52-week range, 97% of the way up
18.1048.78

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

IndexRUT
Employees146
IPOMar 26, 2021
Beta0.38
ATR, 14d2.88
Rel volume0.65
Short float15.37%
Insider own24.57%
Inst own86.78%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap5.23B
Enterprise Value3.49B
Income1.01B
Sales0.00M
Book/sh14.92
Cash/sh15.93
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees146
IPOMar 26, 2021

Ratios

P/E5.84
Forward P/E-
PEG-
P/S-
P/B3.20
P/C3.00
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio12.30
Current Ratio12.30
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)8.18
EPS next Y-1.87
EPS next Q-0.43
EPS this Y667.15%
EPS next Y-120.26%
EPS next 5Y-5.79%
EPS past 3/5Y-8.91% -36.19%
Sales past 3/5Y- -
EPS Y/Y TTM686.34%
Sales Y/Y TTM-
EPS Q/Q2602.62%
Sales Q/Q-
EarningsNov 04 AMC
EPS/Sales Surpr.1913.91% -

Ownership

Insider Own24.57%
Insider Trans-0.91%
Inst Own86.78%
Inst Trans-0.03%
ROA85.43%
ROE92.15%
ROIC61.75%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2018.03%
SMA5015.99%
SMA20029.65%
Trades-

Technical

Shs Outstand109.46M
Shs Float82.58M
Short Float15.37%
Short Ratio8.34
Short Interest12.70M
52W High48.78 -2.09%
52W Low18.10 163.87%
Volatility11.96% 6.85%
ATR (14)2.88
RSI (14)67.98
Beta0.38
Rel Volume0.65
Avg Volume1.52M
Volume642,759

Performance

Perf Week27.26%
Perf Month31.64%
Perf Quarter10.61%
Perf Half Y41.47%
Perf YTD92.46%
Perf Year122.35%
Perf 3Y766.79%
Perf 5Y139.40%
Perf 10Y-
Recom1.15
Target Price55.42
Prev Close46.53
Price47.76
Change %2.64%

Analyst ratings

latest 10 of 15
DateActionAnalystRating changeTargetImplied
Oct 16, 2026InitiatedWWilliam BlairOutperform
Jul 09, 2026InitiatedOOppenheimerOutperform$51+6.8%
Sep 25, 2025InitiatedGGoldmanNeutral$20-58.1%
Jul 30, 2025InitiatedRRaymond JamesStrong Buy$46-3.7%
Jun 30, 2025InitiatedHH.C. WainwrightBuy$42-12.1%
Apr 30, 2025InitiatedGGuggenheimBuy$41-14.2%
Apr 02, 2025DowngradeBScotiabankSector Outperform → Sector Perform$14-70.7%
Mar 07, 2025InitiatedBScotiabankSector Outperform$50+4.7%
Jan 22, 2025InitiatedSStifelHold$30-37.2%
Nov 22, 2024InitiatedEEvercore ISIOutperform$45-5.8%

Peers

Mkt cap
TickerCompanyMkt cap
CYTKCytokinetics Inc8.18B
DYNDyne Therapeutics Inc3.42B
SRPTSarepta Therapeutics Inc1.77B
SLDBSolid Biosciences Inc854.66M
PTCTPTC Therapeutics Inc5.39B
CAPRCapricor Therapeutics Inc615.40M
TNYATenaya Therapeutics Inc86.64M
WVEWave Life Sciences Inc682.41M
BMYBristol-Myers Squibb Co127.28B
LXEOLexeo Therapeutics Inc255.32M

Insider trading

latest 14 of 37
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Nofi MichaelChief Financial OfficerNov 10 '26Option Exercise0.0010,937010,937Nov 10 05:21 PM
Nofi MichaelChief Financial OfficerNov 10 '26Sale45.434,442201,7876,495Nov 10 05:21 PM
Donovan Joanne M.CMOAug 12 '26Option Exercise0.0012,812018,066Aug 14 04:54 PM
Donovan Joanne M.CMOAug 12 '26Sale43.856,522286,00011,544Aug 14 04:54 PM
Donovan Joanne M.CMOAug 13 '26Sale43.412,919126,7048,625Aug 14 04:54 PM
Russell Alan JChief Scientific OfficerAug 12 '26Option Exercise0.0012,812037,367Aug 14 04:53 PM
Russell Alan JChief Scientific OfficerAug 12 '26Sale43.735,901258,04231,466Aug 14 04:53 PM
MOORE JOHN RGeneral CounselAug 12 '26Option Exercise0.0012,499022,713Aug 14 04:53 PM
MOORE JOHN RGeneral CounselAug 12 '26Sale43.825,016219,82317,697Aug 14 04:53 PM
Derakhshan BehradChief Business OfficerAug 12 '26Option Exercise0.0013,281036,926Aug 14 04:53 PM
Derakhshan BehradChief Business OfficerAug 12 '26Sale43.815,100223,42431,826Aug 14 04:53 PM
KOCH KEVINPresident and CEOAug 12 '26Option Exercise0.0039,844070,459Aug 14 04:52 PM
KOCH KEVINPresident and CEOAug 12 '26Sale43.6817,971785,04252,488Aug 14 04:52 PM
JOANNE DONOVANOfficerAug 13 '26Proposed Sale43.562,919127,152Aug 13 04:31 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IHEiShares U.S. Pharmaceuticals ETFAUM: 1.72B
DFASU.S. Small Cap Portfolio-ETF Class Shares-

News

latest 14 of 200
  • Edgewise Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire) +8.21%
  • Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring (PR Newswire)
  • Edgewise Therapeutics Reports Third Quarter 2026 Financial Results (PR Newswire)
  • Serviers $1.55bn muscular dystrophy drug fails Phase II BMD trial (Clinical Trials Arena)
  • Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules (PR Newswire)
  • Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 (PR Newswire)
  • Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules (PR Newswire)
  • Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500 (PR Newswire)
  • Biotech Options Buzz: UTHR, NMRA, EWTX (Schaeffer's Research)
  • Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules (PR Newswire)
  • Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 (PR Newswire)
  • Edgewise Therapeutics Reports Second Quarter 2026 Financial Results (PR Newswire)
  • Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline (PR Newswire) -9.12%
  • Podcast: Servier describes its M&A and manufacturing strategy amidst deal-making drive (Pharmaceutical Technology) +7.56%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-049.650-0.53210.0030.000.009
2026Q22026-08-06-0.530-0.468-0.5320.000.0013
2026Q12026-05-07-0.460-0.485-0.4580.000.0012
2025Q42026-02-26-0.470-0.436-0.4740.000.0012
2025Q32025-11-06-0.390-0.397-0.3860.000.0012
2025Q22025-08-07-0.340-0.414-0.3440.000.0013
2025Q12025-05-08-0.430-0.428-0.4290.000.0010
2024Q42025-03-03-0.420-0.417-0.4190.000.009
2024Q32024-11-07-0.360-0.372-0.3640.000.007
2024Q22024-08-08-0.340-0.345-0.3370.000.007
2024Q12024-05-09-0.330-0.391-0.3260.000.005
2023Q42024-02-22-0.470-0.435-0.4650.000.005
2023Q32023-11-09-0.410-0.396-0.4050.000.005
2023Q22023-08-10-0.340-0.398-0.3390.000.005
2023Q12023-05-11-0.360-0.360-0.3610.000.006
2022Q42023-02-23-0.310-0.336-0.3070.000.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY---0.3480.00-
2021FY-1.140-0.970-0.8650.000.00
2022FY-1.270-1.296-1.2620.000.00
2023FY-1.580-1.542-1.5720.000.00
2024FY-1.450-1.489-1.4480.000.00
2025FY-1.630-1.596-1.6300.000.00
2026FY-9.245--0.00
2027FY--1.873--9.10
2028FY--1.930--54.56
2029FY--2.100--174.17
2030FY--1.123--257.72

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-059000.000.000.00
2026Q4S2026-11-049000.000.000.00
2026Q4S2026-08-069000.000.000.00
2026Q4S2026-06-169000.000.000.00
2026Q4S2026-06-1510000.000.000.00
2026Q4S2026-06-069000.000.000.00
2026Q4S2026-05-0710000.000.000.00
2026Q4S2026-03-1610000.000.000.00
2026Q4S2026-03-059000.000.000.00
2026Q4S2026-02-268000.000.000.00
2026Q4S2025-11-154000.000.000.00
2026Q4S2025-11-115000.000.000.00
2026Q4S2025-11-105000.000.000.00
2026Q4S2025-11-095000.000.000.00

Estimate history

EPS, annual-0.197-0.348-0.865-1.262-1.572-1.448-1.638.184
Period2019202020212022202320242025TTM
EPS, quarterly-0.364-0.419-0.429-0.344-0.386-0.474-0.458-0.5329.648
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual49.21749.21749.563.25770.45394.838106.25109.458
Period2019202020212022202320242025MRQ
Shares, quarterly94.40994.83895.206105.341105.762106.25107.482107.776109.458
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A2.352.272.291.730.540.270.180.12
Gross Profit-2.35-2.27-2.29-1.73-0.54-0.27-0.18-0.12
Selling, General and Administrative Excl. Other215.83189.14156.54112.6271.1242.9417.019.80
Research and Development163.24149.31124.9089.3553.6631.9214.808.50
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-218.18-191.41-158.83-114.36-71.66-43.22-17.19-9.92
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes1,164.93-167.79-133.81-100.16-67.64-42.81-17.12-9.71
Income Taxes155.330.000.000.000.000.000.000.00
Consolidated Net Income1,009.60-167.79-133.81-100.16-67.64-42.81-17.12-9.71
Net Income From Continuing Operations1,009.60-167.79-133.81-100.16-67.64-42.81-17.12-9.71
Net Income1,009.60-167.79-133.81-100.16-67.64-42.81-17.12-9.71
EPS (Recurring)8.35-1.63-1.45-1.57-1.26-0.86-0.35-0.20
EPS (Basic, Before Extraordinaries)9.25-1.63-1.45-1.57-1.26-0.86-0.35-0.20
EPS (Diluted)8.18-1.63-1.45-1.57-1.26-0.86-0.35-0.20
EBITDA-215.83-189.14-156.54-112.62-71.12-42.94-17.01-9.80
Non-Operating Income (Expense)1,383.1123.6125.0214.194.020.400.070.22
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense34.7234.7524.7117.5610.924.400.350.08
Price To Earnings Ratio5.695.69------
Shares Outstanding109.46106.2594.8470.4563.2649.5049.2249.22
Market Capitalization5,094.245,094.242,528.18694.27565.13753.24730.07-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.590.600.590.570.570.570.550.63
Gross Profit-0.59-0.60-0.59-0.57-0.57-0.57-0.55-0.63
Selling, General and Administrative Excl. Other45.5561.3553.5255.4046.2942.0445.4144.91
Research and Development31.0547.0142.1143.0736.9633.0336.2435.79
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-46.14-61.94-54.12-55.98-46.86-42.61-45.96-45.54
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes1,321.48-57.33-49.01-50.22-40.67-36.12-40.80-39.66
Income Taxes155.330.000.000.000.000.000.000.00
Consolidated Net Income1,166.15-57.33-49.01-50.22-40.67-36.12-40.80-39.66
Net Income From Continuing Operations1,166.15-57.33-49.01-50.22-40.67-36.12-40.80-39.66
Net Income1,166.15-57.33-49.01-50.22-40.67-36.12-40.80-39.66
EPS (Recurring)9.65-0.53-0.46-0.47-0.39-0.34-0.43-0.42
EPS (Basic, Before Extraordinaries)10.71-0.53-0.46-0.47-0.39-0.34-0.43-0.42
EPS (Diluted)9.65-0.53-0.46-0.47-0.39-0.34-0.43-0.42
EBITDA-45.55-61.35-53.52-55.40-46.29-42.04-45.41-44.91
Non-Operating Income (Expense)1,367.634.625.105.766.196.505.165.88
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.779.368.719.888.097.739.067.74
Price To Earnings Ratio5.69-------
Shares Outstanding109.46107.78107.48106.25105.76105.3495.2194.84
Market Capitalization5,094.244,371.503,379.042,627.111,708.711,379.172,094.522,528.18

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments530.11470.17318.39351.95280.79129.0923.65
Short Term Receivables0.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets13.285.318.605.052.980.550.39
Total Current Assets543.38475.48327.00357.00283.77129.6524.04
Net Property, Plant & Equipment9.2211.0712.699.850.910.520.50
Total Investments and Advances0.000.000.000.000.000.000.00
Intangible Assets0.00-----0.00
Other Assets0.000.260.350.250.550.970.00
Total Assets552.60486.82340.04367.10285.23131.1424.54
Short Term Debt Incl. Current Port. of LT Debt1.011.000.980.610.000.000.00
Accounts Payable6.015.584.036.113.841.580.67
Other Current Liabilities20.3517.2911.779.876.682.760.47
Total Current Liabilities27.3723.8616.7716.5910.524.341.13
Long Term Debt2.983.744.433.800.00160.2140.26
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.330.000.00
Total Liabilities30.3527.6021.2020.3910.85164.5641.39
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity522.26459.22318.83346.72274.38-33.42-16.85
Total Shareholders Equity522.26459.22318.83346.72274.38-33.42-16.85
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity522.26459.22318.83346.72274.38-33.42-16.85
Total Liabilities & Stockholders Equity552.60486.82340.04367.10285.23131.1424.54
Book Value Per Share4.924.844.535.485.54-0.68-0.34
Tangible Book Value Per Share4.924.844.535.485.54-0.68-0.34
Full-Time Employees14611088593119-
Price to Book Ratio3.125.162.391.562.762.56-
Return on Assets-32.29-32.37-28.33-20.74-20.56-22.00-
Return on Equity-34.19-34.40-30.10-21.78-35.53--
Return on Invested Capital-31.95-28.90-30.98-19.30-15.60-13.50-41.46
Quick Ratio19.8519.9319.5021.5326.9729.8621.24
Current Ratio19.8519.9319.5021.5326.9729.8621.24

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income1,009.60-167.79-133.81-100.16-67.64-42.81-17.12-9.71
Depreciation2.352.272.291.730.540.270.180.12
Other Funds (Non Cash)-1,317.5827.0912.178.0410.384.400.350.08
Funds from Operations-305.63-138.44-119.36-90.39-56.72-38.14-16.58-9.51
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital103.74-5.3710.33-1.564.094.631.950.33
Cash from Operating Activities-201.90-143.82-109.03-91.95-52.63-33.51-14.63-9.17
Capital Expenditures-0.38-0.26-1.31-5.75-5.55-0.67-0.20-0.18
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses1,348.890.000.000.000.000.000.000.00
Purchase or Sale of Investments-1,158.15-32.53-183.34108.63-65.03-241.56-24.180.00
Purchase of Investments-1,641.80-527.23-477.06-255.87-292.39-288.20-24.180.00
Sale Or Maturity of Investments483.65494.69293.71364.50227.3646.640.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities190.36-32.79-184.66102.89-70.58-242.23-24.38-0.18
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock34.02196.09249.5153.33129.89186.38120.2824.80
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock34.02196.09249.5153.33129.89186.38120.2824.80
Proceedsfrom Stock Options0.00187.36239.1552.62129.16186.02120.0824.78
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.200.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities34.21196.09249.2553.17129.64186.38120.2824.80
Net Change in Cash22.6819.48-44.4364.106.43-89.3581.2615.45
Free Cash Flow-202.28-144.07-110.34-97.69-58.18-34.17-14.84-9.35
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments1,743.89460.71499.56530.11563.34593.99
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets28.5810.8110.2313.2810.569.26
Total Current Assets1,772.47471.52509.79543.38573.90603.25
Net Property, Plant & Equipment7.558.178.739.229.5710.08
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets1,780.02479.69518.52552.60583.47613.33
Short Term Debt Incl. Current Port. of LT Debt1.021.021.021.011.011.00
Accounts Payable9.644.677.296.016.168.32
Income Tax Payable108.90-----
Other Current Liabilities24.5423.3614.2320.3514.4811.57
Total Current Liabilities144.1129.0422.5427.3721.6520.90
Long Term Debt2.362.572.782.983.173.37
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.890.000.000.000.000.00
Total Liabilities147.3531.6125.3230.3524.8224.26
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,632.67448.08493.20522.26558.65589.07
Total Shareholders Equity1,632.67448.08493.20522.26558.65589.07
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,632.67448.08493.20522.26558.65589.07
Total Liabilities & Stockholders Equity1,780.02479.69518.52552.60583.47613.33
Book Value Per Share14.924.164.594.925.285.59
Tangible Book Value Per Share14.924.164.594.925.285.59
Full-Time Employees133--146136-
Price to Book Ratio3.128.856.414.702.902.90
Return on Assets85.43-36.09-36.18-32.29-28.73-26.32
Return on Equity92.15-38.03-38.14-34.19-30.02-27.41
Return on Invested Capital71.32-12.72-9.88-9.56-7.24-6.10
Quick Ratio12.3016.2422.6119.8526.5128.87
Current Ratio12.3016.2422.6119.8526.5128.87

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income1,166.15-57.33-49.01-50.22-40.67-36.12
Depreciation0.590.600.590.570.570.57
Other Funds (Non Cash)-1,342.238.557.708.396.035.53
Funds from Operations-175.49-48.18-40.72-41.25-34.07-30.02
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital97.195.71-1.822.66-0.71-2.56
Cash from Operating Activities-78.29-42.47-42.54-38.59-34.78-32.58
Capital Expenditures-0.02-0.03-0.26-0.07-0.09-0.05
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses1,348.890.000.000.000.000.00
Purchase or Sale of Investments-1,289.2078.522.6949.8435.80-162.12
Purchase of Investments-1,404.28-53.09-110.15-74.28-67.00-263.76
Sale Or Maturity of Investments115.08131.61112.84124.12102.80101.65
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities59.6778.492.4349.7635.72-162.17
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock14.982.2912.174.571.66187.63
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock14.982.2912.174.571.66187.63
Proceedsfrom Stock Options0.000.000.000.000.00187.40
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.790.00-0.600.000.60
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities14.983.0912.173.981.66188.23
Net Change in Cash-3.6439.11-27.9415.142.60-6.52
Free Cash Flow-78.31-42.50-42.80-38.66-34.87-32.63

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3015.37%12.7M82.6M1.45M
2026-10-1514.35%11.8M81.9M1.36M
2026-09-3013.70%11.2M81.9M1.33M
2026-09-1511.65%9.5M81.9M1.34M
2026-08-3111.44%9.3M81.7M1.43M
2026-08-1411.85%9.7M81.7M1.41M
2026-07-3112.24%9.8M80.3M1.41M
2026-07-1512.66%10.1M79.6M1.47M
2026-06-3013.19%10.5M79.6M1.41M
2026-06-1512.48%9.9M79.6M1.18M
2026-05-2913.91%10.9M78.5M1.05M
2026-05-1513.20%10.4M78.5M1.03M
2026-04-3013.09%10.1M77.4M910.46K
2026-04-1513.05%10.1M77.2M926.78K
2026-03-3112.30%9.4M76.8M965.24K
2026-03-1312.34%9.5M76.8M1.30M
2026-02-2712.35%9.5M76.8M1.33M
2026-02-1312.53%9.5M75.8M1.40M
2026-01-3012.41%9.5M76.5M1.48M
2026-01-1512.32%9.4M76.5M1.41M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call15.0030.0034.9018.157.6181.000.000.965-0.1690.006
call20.0025.0029.900.005.9180.000.000.953-0.1650.007
call21.0024.0028.900.005.6390.000.000.951-0.1640.008
call22.0023.0027.900.005.3760.000.000.948-0.1630.008
call23.0022.0026.9013.805.0341.000.000.946-0.1620.008
call24.0021.0025.900.004.8870.000.000.942-0.1600.009
call25.0020.0024.9015.024.6596.000.000.939-0.1590.009
call26.0019.0023.9013.934.3591.000.000.936-0.1580.009
call27.0018.0022.9011.484.1541.000.000.896-0.2820.013
call28.0017.0021.7014.693.7865.000.000.891-0.2780.014
call29.0016.0020.100.003.2040.000.000.885-0.2750.014
call30.0015.0019.6011.703.4613.000.000.878-0.2700.015
call31.0014.0018.100.002.8610.000.000.873-0.2660.016
call32.0013.0017.9013.503.2241.000.000.865-0.2610.016
call33.0012.0016.4012.502.6072.000.000.860-0.2580.017
call34.0011.0013.5014.641.2528.000.000.849-0.2500.017
call35.0010.0014.208.301.8892.000.000.841-0.2460.018
call36.009.0013.805.002.2267.000.000.834-0.2420.019
call37.008.0012.403.412.1641190.000.821-0.2330.019
call38.007.1011.903.402.25911.000.000.810-0.2260.020
call39.006.3011.002.902.15425.000.000.797-0.2190.021
call40.005.509.006.601.61029.000.000.780-0.2090.022
call41.004.508.008.491.4192.000.000.766-0.2020.023
call42.004.506.905.651.26216.0015.000.746-0.1910.024
call43.002.906.502.501.39312.000.000.685-0.2730.026
call44.002.206.501.271.6276.000.000.653-0.3070.027
call45.002.704.902.601.21294.000.000.636-0.2400.028
call46.001.755.501.301.34018.000.000.611-0.2580.029
call47.001.154.100.801.28416.000.000.568-0.2380.029
call48.000.004.903.001.4413.000.000.531-0.2410.030
call49.000.454.000.051.4822.000.000.492-0.2350.030
call50.000.553.101.201.61317635.000.461-0.2450.030
call55.000.301.550.301.3981,82145.000.291-0.2010.025
call60.000.200.400.201.1392,08284.000.106-0.0870.014
call65.000.004.900.301.3951590.000.091-0.0950.012
call70.000.003.400.431.62127.000.000.081-0.1010.011
put15.000.004.901.355.2363.000.00-0.035-0.1670.006
put20.000.002.001.604.0455.000.00-0.047-0.1630.007
put21.000.001.800.003.8070.000.00-0.050-0.1600.008
put22.000.001.600.003.5840.000.00-0.053-0.1570.008
put23.000.002.853.903.4761.000.00-0.055-0.1590.008
put24.000.002.251.903.2810.000.00-0.058-0.1560.009
put25.000.002.503.603.0991.000.00-0.062-0.1540.009
put26.000.000.750.052.9614.000.00-0.065-0.1530.009
put27.000.002.850.553.7183.000.00-0.104-0.2780.013
put28.000.002.151.003.5331.000.00-0.110-0.2740.014
put29.000.001.800.553.3593.000.00-0.116-0.2700.014
put30.000.001.800.103.1886060.00-0.122-0.2660.015
put31.000.002.350.053.02287.000.00-0.128-0.2620.016
put32.000.002.952.302.8613.000.00-0.136-0.2570.016
put33.000.004.901.402.70284.000.00-0.143-0.2520.017
put34.000.004.901.242.5481400.00-0.151-0.2470.017
put35.000.002.950.052.4012260.00-0.160-0.2410.018
put36.000.004.901.502.25122.000.00-0.170-0.2350.019
put37.000.004.902.002.1071200.00-0.180-0.2280.019
put38.000.004.602.001.96480.000.00-0.192-0.2210.020
put39.000.004.902.301.82340.000.00-0.205-0.2130.021
put40.000.004.002.501.6872430.00-0.219-0.2050.022
put41.000.002.002.581.59440.000.00-0.229-0.2000.023
put42.000.001.805.001.40610.000.00-0.256-0.1860.024
put43.000.003.404.741.84229.000.00-0.309-0.2670.026
put44.000.004.106.901.67925.000.00-0.333-0.2500.027
put45.000.104.006.301.5215.000.00-0.358-0.2230.028
put46.000.953.800.001.5660.000.00-0.396-0.2390.029
put47.001.454.300.001.5630.000.00-0.432-0.2330.029
put48.000.404.400.001.4470.000.00-0.469-0.2360.030
put49.002.504.900.001.2530.000.00-0.508-0.2290.030
put50.002.504.500.000.9670.000.00-0.566-0.2120.029
put55.005.5010.3022.541.8681.000.00-0.706-0.1990.026
put60.0010.7015.500.002.2840.000.00-0.893-0.0800.014
put65.0016.3020.000.002.4840.000.00-0.909-0.0880.012
put70.0021.3025.000.002.9610.000.00-0.919-0.0930.011

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-104Statement of changes in beneficial ownership of securities2026-11-10SEC
2026-11-05SCHEDULE 13G/ASEC
2026-11-048-KCurrent report2026-11-04SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-08-174/A2026-08-12SEC
2026-08-174/A2026-08-12SEC
2026-08-174/A2026-08-12SEC
2026-08-174/A2026-08-12SEC
2026-08-174/A2026-08-12SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-06SCHEDULE 13GSEC
2026-07-174Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-07-168-K/A2026-07-10SEC
2026-07-138-KCurrent report2026-07-10SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-05SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100201.79K1
2026-100000
2026-090000
2026-08001.90M6
2026-07007.88M1
2026-060000
2026-05002.09M2
2026-0400926.10K1
2026-03001.19M2
2026-020000
2026-01003.40M1
2025-120000
2025-11199.40K12.11M1

Institutional holders

Manager% owned
ORBIMED ADVISORS LLC14.42%
Paradigm Biocapital Advisors LP9.49%
RA CAPITAL MANAGEMENT, L.P.7.80%
BlackRock, Inc.6.14%
Jupiter Topco LLC5.65%
Novo Holdings A/S4.97%
DRIEHAUS CAPITAL MANAGEMENT LLC4.39%
PERCEPTIVE ADVISORS LLC4.07%
VANGUARD CAPITAL MANAGEMENT LLC3.59%
BAKER BROS. ADVISORS LP3.44%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.70%
iShares Russell 2000 ETF1.71%
Strategic Advisers Fidelity U.S. Total Stock Fund1.42%
VANGUARD EXTENDED MARKET INDEX FUND0.80%
Small Cap Growth Fund0.80%
Victory Pioneer Select Mid Cap Growth Fund0.73%
Fidelity Small Cap Index Fund0.73%
Select Biotechnology Portfolio0.64%
Janus Henderson Global Life Sciences Fund0.63%
iShares Russell 2000 Growth ETF0.61%

OakChart. EWTX. Cached 15 minutes.